1 2 3 4 8 11 14

SOTIO and PPF support US regions in fight with COVID-19

Recently SOTIO joined the fight against COVID-19 and supported frontline healthcare professionals in China and the Czech Republic. Now we also supported healthcare workers on the front lines in Boston community. SOTIO, along with our parent company the PPF Group, have donated 60,000 N95 type respirators and 70,000 disposable medical masks to the government of Massachusetts. The Massachusetts Emergency Management Agency (MEMA) met this shipment of essential medical supplies at 6pm Boston time on the 29th of April 2020 and distributed them to local hospitals. Along with PPF and our sister company Home Credit, we have now donated a total of 62,000 respirators and 92,000 medical masks in various regions across the United States, including Kansas City, Washington D.C., New York and Boston. SOTIO is grateful to be able to contribute to the wellbeing of our community beyond just through our fight against cancer.


SOTIO opens office in Basel, Switzerland, to accelerate development of its pipeline products

SOTIO, a biotechnology company owned by the PPF Group, announce today the opening of offices of SOTIO Biotech AG at the Technology Park Basel, Switzerland. The SOTIO office will host the clinical development team, as well as other functions to progress its broad clinical development pipeline towards filing for marketing authorization and commercial launch.


SOTIO’s DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer

  • DCVAC/LuCa decreased the risk of death in patients with stage IV NSCLC by 46%
  • Median overall survival (OS) reached 15.5 months in the treatment arm compared to 11.8 months in the control arm
  • Median Progression Free Survival (PFS) prolonged by 1.1 months
  • Final results of OS and PFS are statistically significant
  • SOTIO considers initiation of Phase II/III clinical trials with DCVAC/LuCa

SOTIO, a biotechnology company owned by the PPF Group, presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer. The final analysis of the data confirmed the promising clinical efficacy of DCVAC/LuCa. SLU01 clinical trial results were presented by the principal investigator Libor Havel, MD, from Thomayer University Hospital in Prague (Czech Republic) at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago today.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies